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ImmunohistochemistrySummary Colorectal cancers (CRC) often show activating mutations of the KRAS or BRAF genes, which
stimulate the extracellular signal-regulated kinase (ERK) pathway, thus increasing cell proliferation and
inhibiting apoptosis. However, immunohistochemical results on ERK activation in such tumors differ great-
ly. Recently, using a highly optimized immunohistochemical method, we obtained evidence that high levels
of ERK activation in rectal adenocarcinomas were associated with resistance to radiochemotherapy. In order
to determine whether KRAS and/or BRAF mutations correlate to immunohistochemically detectable in-
creases in phosphorylation of ERK (pERK), we stained biopsies from 36 CRC patients with activating mu-
tations in the BRAF gene (BRAFV600E: BRAFm), the KRAS gene (KRASm) or in neither (BRAF/KRASn)
with this optimized method. Staining was scored in blind-coded specimens by two observers. Staining of
stromal cells was used as a positive control. BRAFm or KRASm tumors did not show higher staining scores
than BRAF/KRASn tumors. Although BRAFV600E staining occurred in over 90% of cancer cells in all 9
BRAFm tumors, 3 only showed staining for pERK in less than 10% of cancer cell nuclei. The same applied
to 4 of the 14 KRASm tumors. A phophorylation-insensitive antibody demonstrated that lack of pERK stain-
ing did not reﬂect defect expression of ERK1/2 protein. Thus, increased staining for pERKdoes not correlate to
BRAF orKRASmutations even with a highly optimized procedure. Further studies are required to determine
whether this reﬂects differences in expression of counterregulatorymolecules, including ERK phosphatases.
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Stimulation of growth factor receptors activates signaling
pathways, including the ERK/MAPK cascade. Dimerizationr theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
38 S. Holck et al.and autophosphorylation of such receptors recruit adaptor and
docking proteins like GRB2, which, in turn, attracts the gua-
nine nucleotide exchange factor SOS. This leads to activation
of RAS, which initiates the ERK cascade by activating the
MAPK/ERK kinase kinase RAF. In turn, RAF activates the
MAPK/ERK kinases MEK 1 and 2, which activate ERK 1
and 2 by dual threonine/tyrosine phosphorylation [1,2]. Most
of the phosphorylated ERK1 and 2 translocate rapidly to the
nucleus [3] and stimulate transcription of genes involved in
cell cycle progression and cell survival [1,2]. Additionally,
ERK activation is important to stromal cell proliferation and
angiogenesis [4,5] and affords protection against radiation
therapy in vitro [6,7]. In concert with this, radiochemotherapy
has been found to be less efﬁcient in gliomas [8] and rectal ad-
enocarcinomas [9], which express high levels of activated
ERK (pERK).
Overexpression and/or aberrant activation of the epidermal
growth factor (EGF) receptor, (EGFR; ErbB-1; HER1), is fre-
quent in colorectal carcinoma (CRC) and constitutes a thera-
peutic target for monoclonal antibodies and kinase inhibitors
[10]. Activating mutations downstream of EGFR are most
common in RAS or RAF and result in constitutive activation
of ERK. Tumors harboring such mutations may not respond
to EGFR-directed therapies but might respond to RAF or
MEK inhibitors [11,12]. The RAS family of small GTPases in-
cludes three members (KRAS, NRAS and HRAS), and the
RAF family of signal transduction protein kinases also
includes three members (ARAF, BRAF and CRAF). Activating
KRAS mutations, which contraindicate EGFR-directed thera-
py, occur in around 30%–40% and BRAF mutations occur in
around 10% of CRC [12]. With rare exceptions, KRAS and
BRAF mutations are mutually exclusive [12]. The predomi-
nant activating mutation in the BRAF gene substitutes valine
with glutamic acid at position 600 (BRAFV600E), and the
resulting mutant protein can be immunohistochemically de-
tected [13–15]. In contrast, immunohistochemical procedures
for detecting KRAS mutations are not available. Currently,
BRAF mutations are not considered contra-indicative of
EGFR-directed therapies, but detection of such mutations
opens up alternative treatment modalities like RAF inhibitors
[12].
Thus, activating RAS and RAF mutations lead to increased
ERK activation. ERK activation can be immunohistochemi-
cally detected by antibodies, which simultaneously detect dual
phosphorylations on both ERK1 (on Thr202/Tyr204) and
ERK2 (on Thr185/Tyr187). However, in melanomas,
such staining does not correlate to the presence of the
BRAFV600E mutation [16]. Interestingly, heterogeneity of
BRAFV600E expression has been detected in some melano-
mas, suggesting that this mutation may be a secondary event
in such tumors [17]. Moreover, studies of ERK activation in
CRC have yielded divergent results. In one study, cancer cells
of all CRC tumors studied stained [18], whilst others observed
a more differentiated pattern [19,20]. One study reported only
partial correlation to mutation status [19], whilst another study
reported a positive correlation to KRAS mutations [20]. Thesediscrepancies may reﬂect the use of different types of antibod-
ies, use of inefﬁcient demasking techniques (discussed by
Holck et al [9]), of large tissue blocks and/or aged or inappro-
priately ﬁxed material [21–23]. This is particularly important
with respect to phosphoproteins, which rapidly are dephos-
phorylated. Thus, surgical resections that are not immediately
ﬁxed may fail to stain for pERK and other phosphoproteins
[9,22,23]. Fortuitously, stromal cells also show staining for
pERK and this can be used as an internal positive control for
the quality of the ﬁxation and staining in cases where cancer
cells are unreactive [9,16].
In previous studies of pERK in BRAF- or KRAS-mutated
CRC [18–20], material from surgical resections appear to have
been used throughout and use of stromal cells as internal con-
trols was not reported. Different pERK antibodies were used in
the three studies, two monoclonals [18,19] and one polyclonal
[20]. Although all three antibodies were derived from animals
immunized with the relevant phospho-epitope, different re-
sults may ensue because different antibodies may require dif-
ferent primary or secondary structures surrounding the
phosphorylated residues. Moreover, antibodies differ in avid-
ity and low-avidity antibodies may dislocate during washings,
resulting in weakened or indistinct staining [24]. Additional
problems are inherent with polyclonal antibodies, including
the potential presence of antibodies to contaminating proteins,
like keratins from animal keepers [24]. This necessitates the
use of negative controls to document antibody speciﬁcity.
Moreover, positive internal controls, showing staining of stro-
mal cells, are needed to document that delays in ﬁxation have
not affected the results [9,16,24]. As discussed above, this is
particularly important when surgical resections are examined.
In two of the studies cited [19,20] no controls at all were re-
ported and in the third study [18], replacement of the primary
antibody with phosphate-buffered saline served as the only
(negative) control. Unfortunately, this control only examines
whether the secondary antibodies and detection reagents react
with the tissue and tells us nothing about the speciﬁcity of the
primary antibody [24]. Finally, epitope demasking was carried
out using citrate buffers at pH 6 in all three studies [18–20].
This may have compromised detection efﬁciency because
careful comparisons recently carried out in our laboratory doc-
umented that alkaline demasking (pH 9) is far superior to acid-
ic demasking in citrate buffer at pH 6 (compare Fig. 1 A and C
with Fig. 1 B and D by Holck et al [9]).
In the present study, we examined biopsies from CRC tu-
mors harboring activating mutations in the BRAF gene
(BRAFV600E: BRAFm), the KRAS (KRASm) gene or in nei-
ther (BRAF/KRASn) with our highly optimized immunohisto-
chemical method for pERK detection [9]. As documented by
Holck et al [9], the method was optimized by use of small en-
doscopic biopsies that were immediately ﬁxed upon removal,
by the use of alkaline epitope demasking and by the use of
stromal cell staining as an internal positive control. Addition-
ally, we included a number of speciﬁcity controls (dephos-
phorylation, type-matched monoclonal antibodies and
Western blotting) and pERK staining results were compared
Fig. 1 CRC biopsies stained for pERK with the Milan8R antibody (A-D). A, Juxtatumoral area of a BRAF/KRASn tumor (#1536) showing
strong staining of endothelial cell nuclei in capillaries and venules (exempliﬁed by arrowheads) as well as of myoﬁbroblast-like cells. In contrast,
endothelial cells of arterioles and small arteries (asterisks) show more variable staining. Note staining of inﬂammatory cells (arrows) in the lumen
of the arteriole at the bottom. B, Strong staining in nuclei of a majority of tumor cells as well as of myoﬁbroblast-like cells (arrows) in a BRAF/
KRASn tumor (#1536). C, Variable pERK staining in mucosa adjacent to a BRAF/KRASn tumor (#1536). Note staining of part of the surface
epithelium and of some, but not all, crypts. In addition, staining occurs in cells of the lamina propria.
39pERK1/2 and BRAF/KRAS mutation in CRCto stainings with an antibody that does not discriminate be-
tween phosphorylated and non-phosphorylated ERK1/2. In or-
der to exclude a heterogeneous expression of the
BRAFV600E mutation in CRC [as noted in melanomas in
17], the pattern of ERK activation was compared to the expres-
sion pattern of the BRAFV600E protein in BRAFm tumors.2. Materials and methods
2.1. Tumor material
Endoscopic biopsies from 36 cases of CRC were immedi-
ately ﬁxed in 10% formalin and routinely embedded in paraf-
ﬁn. The material was assessed by molecular analysis for
mutations in BRAF and KRAS and tumors with mutations in
the BRAF (n = 9) or the KRAS (n = 14) gene or in neither of
these (n = 13) were selected. Pathological tumor staging, nod-
al metastasis, vascular invasion and differentiation wereassessed on hematoxylin and eosin–stained sections of surgical re-
sections. Patient data are summarized in theTable. The study was
approved by the Danish Data Protection Agency (2008–41-
2252) and Ethical Committee (H-KF-26,288/KF-01-164/03).
2.2. Mutation analysis
KRAS and BRAF mutation analysis was performed using
Roche cobas® K-RAS Mutation Kit (product number
05,852,170,190) (Roche, Pleasanton, CA). The Roche K-
RASmutation assay is a CE-IVD real-time PCRmelting curve
mutation assay without genotyping, detecting 6 speciﬁc muta-
tions in codon 12 (exon 2), 5 mutations in codon 13 (exon 2)
and 6 mutations in codon 61 (exon 3) of the KRAS oncogene.
BRAF mutation analysis was performed using the Roche
cobas® BRAF V600 mutational analysis (product number
05,985,595,190), which evaluates the BRAFV600 site in exon
15 and detects wild-type or mutated V600E. The analyses
were performed according to the manufacturer's instructions
on the z480 Light cycler (Roche).
Table Patient characteristics
BRAFm KRASm BRAF/KRASn
Age: median (range) 76 (55–84) 67 (47–87) 65 (49–83)
Sex 8 female/1male 6 female/8male 4 female/9 male
Location a 7 right/2 left 11 right/3 left 5 right/8 left
T stage 8 T3/1 T4 7 T3/6 T4/1 ND 1 T2/8 T3/4 T4
N stage 1 N0/6 N1/2 N2 1 N0/4 N1/8 N2/1 ND 3 N0/3 N1/7 N2
Vascular invasion 2 cases 5 cases/1 ND 6 cases
MMRP expression 3 normal/6 abnormal 11 normal/1 abnormal/2 ND 13 normal
Differentiation 3 m/5 p/1 u 8 m/6 p 12 m/1 p
Abbreviations: BRAFm, tumors with a BRAFV600E mutation; BRAF/KRASn, tumors with no mutations in the BRAF or KRAS genes according to the testing
panel; KRASm, tumors with activatingKRASmutations; m, moderate glandular differentiation;MMRP, mismatch repair proteins; ND, not determined; p, poor or
mucinous differentiation; u: undifferentiated carcinoma.
a Right denotes caecum, ascending and transverse colon, left denotes descending colon, sigmoid colon and rectum.
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Three-micrometer sections (routine thickness in our labora-
tory) were demasked (PTLink, Dako, Glostrup, Denmark) at
high pH [9] and stained with either of two different mouse
monoclonal antibodies speciﬁc for dually phosphorylated
ERK1/2 (clone Milan8R; mouse IgG1, eBioscience/Affyme-
trix, San Diego, CA as well as clone E10; mouse IgG1,
#9106, Cell Signaling Technology, Danvers, MA, both mono-
clonals recognize phosphorylation of Thr202/Tyr204 in ERK1
and Thr185/Tyr187 in ERK2) [9] as well as with mouse
monoclonals speciﬁc for total ERK1/2 protein, regardless of
phosphorylation status (clone L34F12; mouse IgG1, #4696,
Cell Signaling Technology), BRAFV600E (VE1, Ventana
Medical Systems, Tucson, AZ) or mismatch repair proteins
(MSH6: IR086; MSH2: IR085; MLH1: IR079; PMS2, Dako).
The site of antigen–antibody reaction was detected by a three-
(the MSH2 monoclonal) or two-layer (all remaining monoclo-
nals) polymer peroxidase detection system (Envision, Dako)
using a Dako autostainer, followed by counterstaining with he-
matoxylin. Negative controls included substitution of the
pERK antibodies with a type-matched control mouse IgG1
to Aspergillus niger glucose oxidase, which is absent from
mammals (DAK-GO1, Dako) or dephosphorylation with
4800 units of λ protein phosphatase (New England Biolabs,
Ipswich, MA) in 0.3 ml NEB buffer (50 mM HEPES,
100 mM NaCl, 2 mM DTT, 0.01% Brij 35 pH 7.5, supple-
mented with 1 mMMnCl2) for 60 min at 30°C prior to pERK
staining.2.4. Scoring and statistics
Staining intensities of cancer cell nuclei were scored by two
independent observers in blind-coded specimens as absent (0),
moderate (1) or strong (2), and numbers of stained cancer cell
nuclei were graded as 0% (0), below 10% (1), 10%–60% (2)
and above 60% (3) [8]. The intensity scores were multiplied
with the number scores in order to characterize the overall
staining as absent (0), weak (≤1; exempliﬁed in Fig. 2A, D
and E), intermediate (N1–3) or strong (N3; exempliﬁed inFigs. 1B, 2B and F). Averages of the original scores from both
observers were used for statistical analysis. Statistics were cal-
culated using SAS (version 9.3, SAS Institute, Cary, NC) and
GraphPad Prism (version 4, GraphPad Software, Inc., La Jolla,
CA) with the signiﬁcance level set at 5%.
2.5. Cell culture and Western blotting
Colonic carcinoma (CaCo-2) cells (ATCC/LGCC, Wesel,
Germany), grown in Dulbecco's Modiﬁed Eagle Medium/Nu-
trient Mixture F-12 (Invitrogen, Naerum, Denmark) and 10%
fetal calf serum, were lysed with the MCL1 kit (Sigma, St.
Louis, MO). Protein determination employed the QuantiPro
BCA kit (Sigma). Following electrophoresis on Novex
4%–12% Bis-Tris gels, transfer to PVDFmembranes (Invitro-
gen) and staining with the pERK monoclonal antibodies,
antigen–antibody reactions were detected with alkaline
phosphatase-conjugated antimouse antibody and development
in Novex AP substrate (Invitrogen).3. Results
Biopsies for immunohistochemical analysis were selected
on the basis of prior molecular testing. According to the test
panel (Materials and Methods), 9 cases had BRAFV600E mu-
tations (BRAFm), 14 cases had activating KRAS mutations
(KRASm) and 13 cases had neither BRAF norKRASmutations
(BRAF/KRASn). Patient data are summarized in the Table.
Patients with the BRAFV600E mutation showed a preponder-
ance of right-sided tumors (caecum, ascending and transverse
colon) (78%), poor or mucinous differentiation (67%) and de-
fect mismatch repair protein (MMRP) expression in 6 out of 9
tumors (67%). Defect expression ofMLH1 and PMS2 was de-
tected in 5 of the BRAFm tumors, which showed defect
MMRP expression. This agrees with the previously reported
frequent occurrence of epigenetic silencing of the MLH1 pro-
moter by DNA hypermethylation in tumors with the V600E
BRAFmutation and with the fact that such silencing is accom-
panied by defect PMS2 expression (reviewed by Kawakami
Fig. 2 CRC biopsies stained for pERKwith theMilan8R antibody (A, B, D-F) or for BRAFV600E (C). A, BRAF/KRASn tumor (#1530) show-
ing pERK staining of endothelial cells (exempliﬁed by arrows) and myoﬁbroblast-like cells (exempliﬁed by an arrowhead) but little or no staining
of cancer cells (exempliﬁed by an asterisk) or of inﬂammatory cells (present in the lower left corner). B, BRAF/KRASn tumor (#1536) showing
strong pERK staining of the majority of cancer cell nuclei (exempliﬁed by asterisks) as well as of myoﬁbroblast-like cell nuclei (exempliﬁed by
arrowheads). C and D, BRAFm tumor (#1553) showing staining for the BRAFV600Emutant protein in all cancer cells, but not in stromal cells (C)
whereas staining for pERK only occurs in stromal cells and is absent from the cancer cells in this ﬁeld of vision (D). E, KRASm tumor (#1578)
showing pERK staining of stromal cells but little or no staining of cancer cells. F, KRASm tumor (#1539) showing moderate staining of the ma-
jority of cancer cell nuclei.
41pERK1/2 and BRAF/KRAS mutation in CRCet al and Lipsyc et al [25,26]). Patients with KRASm also
showed a preponderance of right-sided tumors (79%), but only
43% showed poor or mucinous differentiation, and only 1
(9%) showed defect MMRP (MSH2 and MSH6) expression
(Table). Patients with BRAF/KRASn showed no right-sided
preponderance (38%) and no defect MMRP expression.Biopsies were stained for pERK using 2 different monoclo-
nal antibodies (Milan8R and E10). Both antibodies detected
staining of cancer cells and intermingling stromal cells
(Figs. 1 B, 2A and B, D-F). Variable proportions of stromal
and cancer cells were stained in individual tumors but all
showed a uniform staining pattern throughout the block.
ig. 3 Full-length Western blots of CaCo-2 cell lysates stained
ith the pERK monoclonal Milan8R and E10 antibodies. Staining
nly occurs in two bands present at the positions of pERK1 (44-
Da) and pERK2 (42-kDa). Staining of the pERK2 band is strongest,
hich is the case in most tissues.
42 S. Holck et al.Staining was strongest in nuclei and weaker in the cytoplasm
of both cancer and stromal cells (Figs. 1A and B, 2A and B,
D-F). This concurs with data showing that most phophorylated
ERK translocates to the nucleus [3]. Positive stromal cells,
which intermingled with cancer cells, included endothelial
cells and myoﬁbroblast-like cells (Figs. 1B, 2A and B, D-F).
In addition, intra- and extravascular inﬂammatory cells
showed strong nuclear and weaker cytoplasmic staining for
pERK in some (Fig. 1A), but not all (Fig. 2A), specimens.
In the mucosa adjacent to the tumors, staining for pERK
varied considerably evenwithin the same section. Thus, in some
areas, staining of the surface epithelium was marked, whilst
staining was absent from other nearby areas (Fig. 1C). Staining
of endothelial cells and of myoﬁbroblasts in the lamina propria
was also observed (Fig. 1C). All staining detected in the
tumor-adjacent mucosa occurred in both nuclei and cytoplasm
but was strongest in nuclei.
Of the two antibodies tested, the Milan8R antibody pro-
duced crisper staining than the E10 antibody. However, results
obtained were closely similar (vide infra for quantitative re-
sults). Controls, including dephosphorylation prior to immu-
nohistochemical staining for pERK or use of type-matched
control IgG1 were negative. Western blotting of CRC cell ly-
sates detected bands only at the positions of pERK1 and
pERK2 (Fig. 3). With both antibodies, the pERK2 band pre-
dominated, as is the case in most cell types [27].
All specimens were examined by two observers (S.H. and
L.I.L.), who were unaware of the mutation status. Cancer cell
staining for pERK varied considerably between tumors where-
as staining of intermingling stromal cells was constantly pres-
ent. Quantitative results obtained with the Milan8R and the
E10 antibodies showed a very strong correlation (Spearman
ρ = 0.822, P b .0001). Interobserver agreement was highest
for the Milan8R antibody (κ = 0.73) and somewhat poorer
with the E10 antibody (κ = 0.61), which may relate to the
more crisp and clear staining afforded by the former antibody.
Staining for the mutated BRAFV600E protein revealed stain-
ing of over 90% of all cancer cells in all 9 BRAFm tumors
(Fig. 2C). There was no staining for BRAFV600E protein in
stromal cells, nor was staining detected in tumors that were
negative for BRAFm by molecular testing. In 3 of the 9
BRAFm tumors, less than 10% of the cancer cell nuclei stained
for pERK (Fig. 2D), and in 2 of these, cancer cell nuclei were
only weakly stained whilst intermediate nuclear staining inten-
sity occurred in the third tumor. In all of these 3 BRAFm tu-
mors, strong staining of intermingling stromal cell nuclei
was detected, as exempliﬁed in Fig. 2D. In the remaining 6
BRAFm tumors, 10%–60% of all cancer cells showed nuclear
staining, which was of strong intensity in 2 and of intermediate
intensity in 4. Of the KRASm cases, 4 tumors showed pERK
staining in less than 10% of the cancer cell nuclei, and in 2
of these cases only weak nuclear staining occurred (Fig. 2E).
The remaining 10 cases of KRASm tumors showed staining
for pERK in 10%–60% of cancer cell nuclei (Fig. 2F) and in
5 of these cases such staining was strong. Of the BRAF/
KRASn cases, 3 tumors had less than 10% of cells showingF
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wpERK staining in cancer cell nuclei (Fig. 2A), whilst 10 cases
showed staining in 10%–60% of the nuclei (Figs. 1B and 2B).
In 5 of the latter cases, nuclear staining for pERK was strong
(Fig. 1B). In all cases, pERK staining also occurred in adjacent
stromal cells, which intermingled with the cancer cells
(Figs. 1B and 2A and B, D-F). When the numbers of stained
cancer cell nuclei were multiplied with the staining intensities,
weak staining (≤1) was detected in 2 tumors of each category
(exempliﬁed in Fig. 2A, D and E), whilst strong staining (N3)
was detected in 2 (22%) BRAFm tumors, 5 (36%) KRASm tu-
mors and 4 (31%) BRAF/KRASn tumors (exempliﬁed in
Figs. 1B, 2B and F). There were no signiﬁcant differences be-
tween the BRAFm, KRASm and BRAF/KRASn tumor groups
with respect to mean staining for pERK (Fig. 4).
Since differences in expression levels of total ERK1 and 2
protein potentially could explain why not all BRAFm and
Fig. 4 Box-and-whiskers plots showing that pERK staining (cell
number scores multiplied with staining intensity scores) of cancer cell
nuclei does not vary with the mutational status. Horizontal lines indi-
cate medians, boxes indicate interquartile ranges and whiskers indi-
cate total ranges. A Kruskal-Wallis test of all three groups reveal no
signiﬁcant differences (P = .996). Additionally, no signiﬁcant differ-
ences occurred between the individual groups (Mann–Whitney U
test: BRAFm vs BRAF/KRASn: P = .947; KRASm vs BRAF/
KRASn: P = .981; BRAFm vs. KRASm: P = 1.000).
ig. 5 Box-and-whiskers plot of cytoplasmic (left) and nuclear
ight) staining scores for ERK1/2 protein versus nuclear staining
cores for pERK. Note that also cancer cells, which lack signiﬁcant
uclear pERK staining, contain substantial cytoplasmic stores of
RK1/2 protein, whereas nuclear staining scores for ERK1/2 protein
ary in parallel with nuclear staining scores for pERK. The P values
fer to Mann–Whitney U tests.
43pERK1/2 and BRAF/KRAS mutation in CRCKRASm tumors showed evidence of increased ERK activa-
tion, we stained all tumors with an antibody that did not dis-
criminate between phosphorylated and non-phosphorylated
ERK1/2. All tumors showed cytoplasmic staining of cancer
cells. In addition, some tumors showed nuclear staining of can-
cer cells, whilst stromal cells (endothelial cells and
myoﬁbroblast-like cells) showed cytoplasmic and variable nu-
clear staining. Variable degrees of staining were also observed
in nuclei and cytoplasm of inﬂammatory cells. Blind-coded
specimens were scored for nuclear and cytoplasmic staining
of cancer cells. There were no signiﬁcant differences in total
ERK1/2 protein staining of either cancer cell cytoplasm or nu-
clei between the BRAFm, KRASm and BRAF/KRASn tumor
groups (data not shown). Importantly, the cancer cells, regard-
less of whether or not they contained pERK, expressed ERK1/
2 protein in the cytoplasm. Moreover, scorings showed that
levels of cytoplasmic ERK1/2 protein did not differ between
cancer cells that contained high and low levels of pERK
(Fig. 5). This was also evident from studies of adjacent
sections stained for pERK and for ERK1/2 protein (Fig. 6A
and B). These results deﬁnitely prove that deﬁcient ERK phos-
phorylation in some of the cancers does not reﬂect deﬁcient
ERK1/2 protein expression. In agreement with the fact that
phosphorylation of ERK1/2 is needed for its translocation into
the nucleus [3], tumors having cancer cells with pERK-
positive nuclei contained comparable numbers of nuclei stain-
ing for ERK1/2 protein (Figs. 5B, 6C and D).4. Discussion
We have previously shown that immunohistochemical
staining for pERK can be highly optimized by alkaline
demasking [9]. This results in muchmore intense staining than
citrate buffer demasking, which is recommended by theF
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reantibody vendors and which has been used in most previous
studies [16,18–20]. Additionally, endoscopic biopsies that im-
mediately were ﬁxed upon removal were used. This is impor-
tant because variations in ischemia time may compromise
staining of these highly labile phosphoepitopes [9,16,21–23].
Moreover, staining of stromal cells served as a valuable inter-
nal positive control and was uniform throughout the blocks
with no evidence of a gradient. The staining of stromal cells
in CRC was not unexpected because ERK activation is impor-
tant both to angiogenesis and ﬁbroblast proliferation [4,5] –
phenomena that characterize most cancers. Staining of
tumor-adjacent mucosa was very variable, even within the
same biopsy, and was therefore not useful as an internal posi-
tive control. This variability may conceivably relate to effects
like pressure or other inﬂuences of the tumor on adjacent mu-
cosa, to differences in patient age, to the degree of concomitant
inﬂammation and/or to different types of enemas administered
prior to endoscopy. Two different monoclonal pERK antibod-
ies produced identical results but the Milan8R antibody was
preferred because it produced more crisp staining than the
E10 antibody. Interobserver agreement was better with the
Milan8R antibody than with the E10 antibody, which may re-
ﬂect the clearer staining afforded by this antibody. Neverthe-
less, there was a very strong correlation between results
obtained by both antibodies. Three controls for the speciﬁcity
of the staining were performed. Firstly, the primary pERK an-
tibody was substituted for a type-matched IgG1monoclonal of
irrelevant speciﬁcity, and this resulted in no staining. Second-
ly, in sections that were dephosphorylated prior to immunohis-
tochemistry for pERK no staining occurred. Thirdly, we used
Fig. 6 Adjacent sections of tumors stained for pERK (Milan8R)
and total ERK1/2 protein. A and B, BRAFm tumor (#1521), showing
little or no pERK staining in cancer cells but uniform cytoplasmic
staining for ERK1/2 protein. Note also positive staining for both
pERK and ERK1/2 protein in stromal cells. C and D, KRASm tumor
(#1510), showing strong nuclear and weaker cytoplasmic staining for
both pERK and for ERK1/2 protein.
44 S. Holck et al.Western blots of cultured CRC cells to avoid contributions
from intermingling stromal cells, and such blots revealed two
bands in the positions expected for pERK1 and pERK2 and
no additional bands.
The purpose of the present study was to examine whether
the optimized procedure for pERK immunohistochemistry
could detect differences in ERK activation between CRCs
with or without activating mutations in the KRAS or BRAF
genes. Thus, previous studies on CRC have yielded somewhat
conﬂicting data [18–20], whereas studies of melanomas have
shown little correlation between expression of the predomi-
nant BRAF mutation (BRAFV600E) and ERK activation
[16]. Previous studies have also demonstrated cell heterogene-
ity with respect to expression of this BRAF mutation in some
melanomas [17]. Potentially, such heterogeneity could trans-
late into heterogeneous ERK activation. We therefore also
stained the CRC tumors with an antibody detecting themutated BRAFV600E protein and examined blind-coded
specimens. Staining for BRAFV600E did, in agreement with
previous studies [13–15], correlate perfectly with the results
of molecular testing. Moreover, at least 90% of all cancer cells
stained for the mutated BRAFV600E protein in all 9 BRAFm
tumors examined. In contrast, pERK staining was present in
less than 10% of all cancer cells in 3 of these tumors. However,
even in these 3 cases, strong pERK staining was present in nu-
clei of intermingling stromal cells. Thus, we obtained no evi-
dence for heterogeneous expression of BRAFV600E in CRC
and conclude that BRAFV600E expression and ERK activa-
tion do not correlate. Similarly, less than 10% of cancer cell
nuclei in 4 KRASm tumors and in 3 BRAF/KRASn tumors
stained for pERK even under these highly optimized condi-
tions. Although the number of investigated tumors is compar-
atively small (n = 36), the essential point is that several tumors
with documented BRAF (n = 3) or KRAS (n = 4) mutations
showed staining for pERK in only few of all cancer cell nuclei
and that this staining, moreover, was weak in 2 of the BRAFm
and in 2 of the KRASm tumors. Inclusion of more patients
would not change this evident discrepancy between activating
mutations in the pathway and ERK phosphorylation.
A caveat of this, and previous, studies of correlations
between RAS mutations and ERK activation is that not all
possible activating mutations in the RAS genes could be tested
for (cf. new guidelines discussed by Atreya et al [12]). Thus, it
cannot be formally excluded that an occasional patient in the
BRAF/KRASn group could harbor RAS mutations not tested
for (for example in KRAS codons 117 or 146 of exon 4 or in
NRAS). However, NRAS mutations only occur in only about
3%–6% of CRC tumors, and mutations in KRAS codons 117
or 146 of exon 4 occur in 6%–7% [12,25]. Again, however,
the essential point raised by our results is that tumors proven
to have activating BRAF orKRASmutations do not necessarily
show uniformly high ERK activation. Thus, the fact that all
BRAFV600E-mutated tumors expressed the mutant protein
in over 90% of the cells, whilst pERK was detectable in less
than 10% of all cancer cells in 3 BRAFm cases drives home
the fact that there is no obligate correlation between BRAF
mutations and ERK activation. Since similar ﬁndings were
made with the KRAS-mutated group we may infer a similar
lack of correlation here, but with the proviso that no immuno-
histochemical method for localizing the multiple forms of mu-
tated RAS proteins exists.
Thus, even with an optimized method, pERK staining can-
not be used as a surrogate marker for activating BRAF or
KRAS mutations in CRC. This concurs with previous ﬁndings
using the less efﬁcient citrate demasking method in CRC
[18,19] or in melanomas [16]. Moreover, studies of transgenic
mouse models concur with this by showing no obligatory as-
sociation between activatingKRASmutations and ERK activa-
tion (reviewed by Deschênes-Simard et al [28]). Our staining
results for total ERK protein clearly demonstrate that the fail-
ure of some BRAFm and KRASm tumors to show signiﬁcant
ERK phosphorylation is not due to defect expression of ERK
protein. Thus, cytoplasmic staining for total ERK protein did
45pERK1/2 and BRAF/KRAS mutation in CRCnot differ between tumors showing weak or strong pERK
staining (or between mutated and BRAF/KRASn tumors). In
contrast, nuclear staining for total ERK showed excellent cor-
relation to nuclear staining for pERK. This reﬂects the fact that
ERK can only be imported into the nucleus when phosphory-
lated [3] and adds further credence to the validity of the immu-
nohistochemical method for pERK.
Mechanisms which regulate the magnitude and duration of
ERK activation may conceivably explain why pERK is only
detectable at a low level in some of the BRAFm or KRASm tu-
mors. Thus, ERK phosphorylation is typically transient be-
cause several mechanims limit its duration (reviewed by
Larsson and Holck [2]). These mechanisms profoundly affect
the biological outcome of ERK activation because transient
activation stimulates cell proliferation, whilst prolonged acti-
vation induces differentiation and senescence [28]. This has
been noted to occur also in the context of BRAF mutations
[29]. Downregulating mechanisms include MAP kinase phos-
phatases (MKPs, also referred to as dually speciﬁc phospha-
tases: DUSPs), which dephosphorylate pERK [30].
Expression levels and stabilities ofMKPs are tightly regulated,
both by pERK [31,32] and by the stress-activated protein ki-
nases p38 and Jun N-terminal kinase [32,33]. Additional regu-
lating mechanisms exist, including interactions with the
AKT–mTOR pathway, with RAF kinase inhibitors, with
Sprouty and with scaffolding proteins like IQGAP1
[16,34–36]. Interestingly, expression levels of MKP-1,
MKP-2 and IQGAP1 vary between tumors and correlate with
tumor behavior [36–38]. Further studies are needed to deter-
mine whether these mechanisms contribute to the discrepan-
cies between BRAF and KRAS mutations and ERK activation
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